Osiris Therapeutics Wins Top Scoring Abstract at the 24th Annual Symposium on Advanced Wound Care
Three abstracts describing the science and initial clinical results of
the Osiris Biosurgery product Grafix® to be presented at
leading wound care conference
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ:OSIR) today announced that three
abstracts describing the science and initial clinical evaluation of
Grafix, a cellular wound care dressing, in the limb salvage and
recalcitrant wound setting were accepted for presentation at the 24th
Annual Symposium on Advanced Wound Care and Wound Healing Society. The
abstract, "Characterization of novel human mesenchymal stem
cell-containing skin substitutes for the treatment of wounds" by lead
author Dr. Dana Yoo, was awarded the top score of all entries to the
meeting as determined by a blinded review panel that evaluated
submissions for their importance and relevance to the field of wound
care research. Dr. Yoo will give a podium presentation on the subject in
Session 41.1 on April 16.
Grafix is a living skin substitute comprised of a biologic membrane
containing endogenous mesenchymal stem cells (MSCs) that is used to
promote healing in chronic wounds, limb salvage procedures, and burns.
Studies have demonstrated that Grafix contains the necessary components
for optimal dermal repair including sustained expression of an array of
growth factors and cytokines that limit inflammation and promote each
phase of wound healing.
"Chronic wounds remain a debilitating and at times life-threatening
problem for over 5 million people in the United States alone," said
Walter A. Conlan III, M.D., CWS, Medical Director of the Wound Healing
Center at Osceola Regional Medical Center and Grafix investigator.
"Research has shown that stem cells have the unique ability to provide
trophic support and control unwanted inflammation, making them an ideal
candidate in the chronic wound setting. At our center, we were able to
safely close chronic wounds with Grafix that were otherwise unresponsive
to advanced therapies. Grafix should be considered in the management of
patients with chronic wounds that are non-responsive to conventional
treatment."
On April 16 (Session 41.2) Dr. Conlan will give a podium presentation
entitled, "The use of a novel, human mesenchymal stem cell-containing
skin substitute in the treatment of refractory wounds: a case series,"
describing the performance of the product in patients with difficult to
treat wounds that have failed at least one advanced therapy.
The abstract entitled, "Limb salvage utilizing a human mesenchymal stem
cell-containing skin substitute: results of a case series in patients
with diabetic foot ulcers" will also be presented in the poster session
on April 15. This study demonstrated the utility of Grafix as a salvage
treatment in patients with severe wounds who were at risk for amputation
from diabetic foot ulcers.
While at SAWC visit Osiris at booth 938.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is the leading stem cell company focused on
developing products to treat serious medical conditions in the
inflammatory, autoimmune, orthopedic, wound care and cardiovascular
areas. The company's pipeline of internally developed biologic drug
candidates under evaluation includes Prochymal for inflammatory,
autoimmune and cardiovascular indications, as well as Chondrogen for
arthritis in the knee. Osiris is a fully integrated company, with
capabilities in research, development, manufacturing and distribution of
stem cell products. Osiris has developed an extensive intellectual
property portfolio to protect the company's technology, including 47
U.S. and over 300 foreign patents. Osiris and Prochymal are registered
trademarks of Osiris Therapeutics, Inc. More information can be found on
the company's website, www.Osiris.com.
(OSIR-G)
Osiris and Genzyme formed a strategic alliance for the development and
commercialization of Prochymal and Chondrogen. Under the terms of the
agreement, Osiris retains commercialization rights to Prochymal and
Chondrogen in the United States and Canada. Genzyme holds these rights
in all other countries except Japan, where JCR Pharmaceuticals holds
rights to Prochymal for the treatment of patients with hematological
malignancies.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking
statements include statements about our expectations, beliefs, plans,
objectives, intentions, assumptions and other statements that are not
historical facts. Words or phrases such as "anticipate," "believe,"
"continue," "ongoing," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project" or similar words or phrases, or the
negatives of those words or phrases, may identify forward-looking
statements, but the absence of these words does not necessarily mean
that a statement is not forward-looking. Examples of forward-looking
statements include, but are not limited to, statements regarding the
following: our product development efforts; our clinical trials and
anticipated regulatory requirements and the ability to successfully
navigate these requirements; the success of our product candidates in
development; status of the regulatory process for our biologic drug
candidates; implementation of our corporate strategy; our financial
performance; our product research and development activities and
projected expenditures, including our anticipated timeline and clinical
strategy for Prochymal, Chondrogen and our other MSC and biologic drug
candidates; our cash needs; patents and proprietary rights; the safety
and ability of our potential products to treat disease and the results
of our scientific research; our plans for sales and marketing; our plans
regarding our facilities; types of regulatory frameworks we expect will
be applicable to our potential products; and results of our scientific
research. Forward-looking statements are subject to known and unknown
risks and uncertainties and are based on potentially inaccurate
assumptions that could cause actual results to differ materially from
those expected or implied by the forward-looking statements. Risks and
uncertainties related to our Collaboration Agreement with Genzyme for
the development and commercialization of Prochymal and Chondrogen
include, among others: typical business transactional risks; risks
related to product development and clinical trial design, performance
and completion; uncertainty of the success of Prochymal and Chondrogen
in clinical trials and their ability to treat disease; Genzyme's early
termination and opt-out rights; the ability of Osiris and Genzyme to
successfully navigate regulatory requirements and to manufacture and
commercialize products; and the uncertainty as to our ability to
successfully perform under the collaborative arrangement and earn
milestone and royalty payments thereunder. Our actual results could
differ materially from those anticipated in forward-looking statements
for many reasons, including the factors described in the section
entitled "Risk Factors" in our Annual Report on Form 10-K and other
Periodic Reports filed on Form 10-Q, with the United States Securities
and Exchange Commission. Accordingly, you should not unduly rely on
these forward-looking statements. We undertake no obligation to publicly
revise any forward-looking statement to reflect circumstances or events
after the date of this press release or to reflect the occurrence of
unanticipated events.
Osiris Therapeutics, Inc.
Erica Elchin, 443-545-1834
OsirisPR@Osiris.com
Source: Osiris Therapeutics, Inc.
News Provided by Acquire Media
Print page |
E-mail page
| 
Download PDF
|
Add to briefcase